S&P 500   3,849.62
DOW   30,937.04
QQQ   328.59
pixel
S&P 500   3,849.62
DOW   30,937.04
QQQ   328.59
pixel
S&P 500   3,849.62
DOW   30,937.04
QQQ   328.59
pixel
S&P 500   3,849.62
DOW   30,937.04
QQQ   328.59
pixel
Log in
NASDAQ:HARP

Harpoon Therapeutics Stock Forecast, Price & News

$20.72
-0.20 (-0.96 %)
(As of 01/26/2021 12:00 AM ET)
Add
Compare
Today's Range
$20.30
Now: $20.72
$21.15
50-Day Range
$12.83
MA: $18.23
$24.16
52-Week Range
$10.27
Now: $20.72
$25.24
Volume115,098 shs
Average Volume386,029 shs
Market Capitalization$525.87 million
P/E RatioN/A
Dividend YieldN/A
Beta0.87
Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company's lead TriTAC product candidate is HPN424 that is in Phase I clinical trial for the treatment of metastatic castration-resistant prostate cancer. It also develops HPN536, which is in Phase I/IIa clinical trial for the treatment of ovarian cancer and other MSLN-expressing tumors; HPN217 for the treatment of multiple myeloma; and HPN328 for the treatment of SCLC. The company has a collaboration agreement with AbbVie Biotechnology Ltd. Harpoon Therapeutics, Inc. was founded in 2015 and is headquartered in South San Francisco, California.

MarketRank

Overall MarketRank

1.49 out of 5 stars

Medical Sector

428th out of 1,925 stocks

Biological Products, Except Diagnostic Industry

55th out of 177 stocks

Analyst Opinion: 3.5Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:HARP
CUSIPN/A
CIKN/A
Phone650-443-7400
Employees77
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$5.78 million
Book Value$3.82 per share

Profitability

Net Income$-55,570,000.00
Net Margins-434.74%

Miscellaneous

Market Cap$525.87 million
Next Earnings Date3/11/2021 (Estimated)
OptionableNot Optionable
$20.72
-0.20 (-0.96 %)
(As of 01/26/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive HARP News and Ratings via Email

Sign-up to receive the latest news and ratings for HARP and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Harpoon Therapeutics (NASDAQ:HARP) Frequently Asked Questions

How has Harpoon Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Harpoon Therapeutics' stock was trading at $13.07 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, HARP shares have increased by 58.5% and is now trading at $20.72.
View which stocks have been most impacted by COVID-19
.

Is Harpoon Therapeutics a buy right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Harpoon Therapeutics in the last twelve months. There are currently 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Harpoon Therapeutics stock.
View analyst ratings for Harpoon Therapeutics
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Harpoon Therapeutics?

Wall Street analysts have given Harpoon Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Harpoon Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Gerald McMahon's approval rating as Harpoon Therapeutics' CEO?

4 employees have rated Harpoon Therapeutics CEO Gerald McMahon on Glassdoor.com. Gerald McMahon has an approval rating of 100% among Harpoon Therapeutics' employees. This puts Gerald McMahon in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

When is Harpoon Therapeutics' next earnings date?

Harpoon Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, March 11th 2021.
View our earnings forecast for Harpoon Therapeutics
.

How were Harpoon Therapeutics' earnings last quarter?

Harpoon Therapeutics, Inc. (NASDAQ:HARP) released its earnings results on Wednesday, November, 4th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.49) by $0.04. The firm earned $3.89 million during the quarter, compared to analyst estimates of $4.60 million. Harpoon Therapeutics had a negative net margin of 434.74% and a negative trailing twelve-month return on equity of 68.32%.
View Harpoon Therapeutics' earnings history
.

What price target have analysts set for HARP?

8 equities research analysts have issued 1 year price targets for Harpoon Therapeutics' stock. Their forecasts range from $25.00 to $38.00. On average, they expect Harpoon Therapeutics' stock price to reach $31.50 in the next twelve months. This suggests a possible upside of 52.0% from the stock's current price.
View analysts' price targets for Harpoon Therapeutics
or view Wall Street analyst' top-rated stocks.

Who are some of Harpoon Therapeutics' key competitors?

What other stocks do shareholders of Harpoon Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Harpoon Therapeutics investors own include Sorrento Therapeutics (SRNE), Inovio Pharmaceuticals (INO), Alector (ALEC), Precision BioSciences (DTIL), Editas Medicine (EDIT), Gossamer Bio (GOSS), Kaleido Biosciences (KLDO), NVIDIA (NVDA), Ovid Therapeutics (OVID) and Advanced Micro Devices (AMD).

Who are Harpoon Therapeutics' key executives?

Harpoon Therapeutics' management team includes the following people:
  • Dr. Gerald McMahon, Pres, CEO & Director (Age 66, Pay $749.11k)
  • Ms. Georgia L. Erbez, Chief Financial Officer (Age 54, Pay $500.79k)
  • Dr. Natalie R. Sacks, Chief Medical Offer (Age 56, Pay $538.42k)
  • Dr. Holger Wesche Ph.D., Chief Scientific Officer (Age 53)
  • Ms. Rachael Lester, VP of Corp. Devel.
  • Dr. Susan Dana Jones Ph.D., Sr. VP of Product Devel.
  • Dr. Che-Leung Law Ph.D., Sr. VP of Translational Medicine
  • Mr. Christopher Whitmore, VP of Fin. & Sec.

When did Harpoon Therapeutics IPO?

(HARP) raised $76 million in an IPO on Friday, February 8th 2019. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. Citigroup and Leerink Partners acted as the underwriters for the IPO and Canaccord Genuity and Wedbush PacGrow were co-managers.

What is Harpoon Therapeutics' stock symbol?

Harpoon Therapeutics trades on the NASDAQ under the ticker symbol "HARP."

How do I buy shares of Harpoon Therapeutics?

Shares of HARP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Harpoon Therapeutics' stock price today?

One share of HARP stock can currently be purchased for approximately $20.72.

How big of a company is Harpoon Therapeutics?

Harpoon Therapeutics has a market capitalization of $525.87 million and generates $5.78 million in revenue each year. The company earns $-55,570,000.00 in net income (profit) each year or ($2.55) on an earnings per share basis. Harpoon Therapeutics employs 77 workers across the globe.

What is Harpoon Therapeutics' official website?

The official website for Harpoon Therapeutics is www.harpoontx.com.

How can I contact Harpoon Therapeutics?

Harpoon Therapeutics' mailing address is 131 OYSTER POINT BLVD SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 650-443-7400 or via email at [email protected]

This page was last updated on 1/27/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.